Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.1.1.67 - thiopurine S-methyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Agranulocytosis
[Significance of thiopurine s-methyltransferase gene test in a clinical case].
Anemia
Expressing thiopurine S-methyltransferase activity as units per litre of whole-blood overcomes misleading high results in patients with anaemia.
Anemia, Aplastic
Aplastic anemia secondary to azathioprine in systemic lupus erythematosus: report of a case with normal thiopurine S-methyltransferase enzyme activity and review of the literature.
Arthritis, Rheumatoid
Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis.
Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography.
High frequency of mutant thiopurine S-methyltransferase genotypes in Mexican patients with systemic lupus erythematosus and rheumatoid arthritis.
Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients?
Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis.
Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies.
Aspergillosis
Severe pancytopenia and aspergillosis caused by thioguanine in a thiopurine S-methyltransferase deficient patient: a case report.
Autoimmune Diseases
Allelic variants of the thiopurine methyltransferase (TPMT) gene in the Colombian population.
Assessment of thiopurine methyltransferase activity in patients prescribed azathioprine or other thiopurine-based drugs.
Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis.
Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals.
Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia.
Genetic polymorphism of thiopurine S-methyltransferase in Argentina.
Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases.
Genotyping of thiopurine methyltransferase using pyrosequencing.
In Vitro Protein Stability of Two Naturally Occurring Thiopurine S-Methyltransferase Variants: Biophysical Characterization of TPMT*6 and TPMT*8.
Red Blood cell IMPDH activity in adults and children with or without azathioprine: Relationship between thiopurine metabolites, ITPA and TPMT activities.
The use of denaturing high-pressure liquid chromatography for the detection of mutations in thiopurine methyltransferase.
Thiopurine S-methytransferase Gene Polymorphism in Rheumatoid Arthritis.
[Significance of thiopurine s-methyltransferase gene test in a clinical case].
beta-Thalassemia
Arrayed primer extension: a robust and reliable genotyping platform for the diagnosis of single gene disorders: beta-thalassemia and thiopurine methyltransferase deficiency.
Brain Neoplasms
High incidence of secondary brain tumours after radiotherapy and antimetabolites.
Breast Neoplasms
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Misinterpretation of TPMT by a DTC Genetic Testing Company.
Carcinoma
Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA.
Cardiotoxicity
Acute lymphoblastic leukemia.
Cholangitis, Sclerosing
Autoimmune hepatitis with sclerosing cholangitis in a patient with thiopurine methyltransferase deficiency: case presentation.
Colitis, Ulcerative
Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls.
Whole-Blood Thiopurine S-Methyltransferase Genotype and Phenotype Concordance in Iranian Kurdish Ulcerative Colitis (UC) Patients.
Colorectal Neoplasms
A personalized approach to cancer treatment: how biomarkers can help.
Crohn Disease
5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
Analysis of thiopurine S-methyltransferase phenotype-genotype in a Tunisian population with Crohn's disease.
Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study.
Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease.
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.
Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease.
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression.
NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn's disease.
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.
Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy.
Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease.
The Current Relevance of Pharmacogenetics in Immunomodulation Treatment for Crohn's Disease.
The Identification of a Novel Thiopurine S-Methyltransferase Allele, TPMT*45, in Korean Patient with Crohn's Disease.
Thiopurine methyltransferase genotype distribution in patients with Crohn's disease.
Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity-A Retrospective Study.
[Significance of thiopurine s-methyltransferase gene test in a clinical case].
Cystic Fibrosis
Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts.
Dermatitis, Atopic
A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression.
Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency.
Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial.
Life threatening myelotoxicity secondary to azathioprine in a patient with atopic eczema and normal thiopurine methyltransferase activity.
[Safety of azathioprine therapy adjusted to thiopurine methyltransferase activity in the treatment of infantile atopic dermatitis. Report on 7 cases]
Drug-Related Side Effects and Adverse Reactions
A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.
Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).
Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis.
Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis.
Automation of the Whole-Blood Thiopurine S-Methyltransferase (TPMT) Phenotyping Assay Using the Biomek NXP and Biomek i5 Liquid-Handling Workstations.
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.
Determination of ITPase activity in erythrocyte lysates obtained for determination of TPMT activity.
Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease.
Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events.
No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease.
Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation.
Pre-analytic and analytic sources of variations in thiopurine methyltransferase activity measurement in patients prescribed thiopurine-based drugs: A systematic review.
Predicting drug response and toxicity based on gene polymorphisms.
Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients.
Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease.
Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy.
The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases.
Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.
Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment.
Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.
Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review.
Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy.
Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism.
Eczema, Dyshidrotic
Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase.
Detection of a Novel Single Nucleotide Polymorphism of the Human Thiopurine S-Methyltransferase gene in a Chinese Individual.
Febrile Neutropenia
Acute lymphoblastic leukemia.
Hearing Loss
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset.
Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Hematologic Neoplasms
Consequences of binding an S-adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone.
Structural and functional impact of missense mutations in TPMT: An integrated computational approach.
Tertiary structure of thiopurine methyltransferase from Pseudomonas syringae, a bacterial orthologue of a polymorphic, drug-metabolizing enzyme.
Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Hepatic Veno-Occlusive Disease
TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Hepatitis, Autoimmune
Autoimmune hepatitis with sclerosing cholangitis in a patient with thiopurine methyltransferase deficiency: case presentation.
Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people.
Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.
Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis.
Cost-effectiveness of pharmacotherapy for autoimmune hepatitis.
NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis.
Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis.
Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis.
Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis.
[Thiopurine methyltransferase activity in patients with autoimmune hepatitis]
Hypersensitivity
Azathioprine hypersensitivity syndrome: a case report.
Azathioprine hypersensitivity syndrome: report of two cases with cutaneous manifestations.
Methodological and statistical issues in pharmacogenomics.
Overview of the pharmacoeconomics of pharmacogenetics.
Idiopathic Pulmonary Fibrosis
Erratum to: Thiopurine S-Methyltransferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis.
Infections
Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis.
Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil.
Inflammatory Bowel Diseases
A Practical Non-Extraction Direct Liquid Chromatography Method for Determination of Thiopurine S-Methyltransferase Activity in Inflammatory Bowel Disease.
A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs.
Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease.
Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases.
Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease.
Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.
Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis.
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.
Characterisation of novel defective thiopurine S-methyltransferase allelic variants.
Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients.
Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs.
Cost-effectiveness analysis of genotype screening and therapeutic drug monitoring in patients with inflammatory bowel disease treated with azathioprine therapy: a Chinese healthcare perspective using real-world data.
Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
Deletion of Glutathione-S-Transferase M1 Reduces Azathioprine Metabolite Concentrations in Young Patients With Inflammatory Bowel Disease.
Determination of thiopurine S-methyltransferase activity by hydrophilic interaction liquid chromatography hyphenated with mass spectrometry.
Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients.
Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease.
Four human thiopurine s-methyltransferase alleles severely affect protein structure and dynamics.
Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders.
High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease.
High-resolution melting analysis of the TPMT gene: a study in the Polish population.
Impracticalities of thiopurine S-methyltransferase determination in daily inflammatory bowel disease practice.
Influences of Thiopurine Methyltransferase Genotype and Activity on Thiopurine-induced Leukopenia in Korean Patients With Inflammatory Bowel Disease: A Retrospective Cohort Study.
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.
Monitoring azathioprine metabolite levels and thiopurine methyl transferase (TPMT) activity in children with inflammatory bowel disease.
Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease.
No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease.
Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease.
Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism.
Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.
Pharmacogenetics of drug metabolizing enzyme: thiopurine methyl transferase phenotypes and multidrug resistance 1 gene polymorphism in inflammatory bowel disease.
Pharmacogenomics in inflammatory bowel disease.
Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.
Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece.
Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine.
Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine.
Review article: thiopurines in inflammatory bowel disease.
Role of Thiopurine Metabolite Testing and Thiopurine Methyltransferase Determination in Pediatric IBD.
Structural and functional impact of missense mutations in TPMT: An integrated computational approach.
Structural Characteristics Determine the Cause of the Low Enzyme Activity of Two Thiopurine S-Methyltransferase Allelic Variants: A Biophysical Characterization of TPMT*2 and TPMT*5.
Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies.
The Role of Inosine-5'-Monophosphate Dehydrogenase in Thiopurine Metabolism in Patients With Inflammatory Bowel Disease.
The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.
The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease.
Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Thiopurine metabolites and the role of thiopurine methyltransferase activity in inflammatory bowel disease.
Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.
Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.
Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs.
Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events.
Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.
Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Thiopurine Methyltransferase genetic polymorphisms and activity and metabolic products of azathioprine in patients with inflammatory bowel disease.
Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease.
Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.
Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment.
Thiopurine S-methyltransferase as a target for drug interactions.
Thiopurine s-methyltransferase gene polymorphisms in a healthy slovak population and pediatric patients with inflammatory bowel disease.
Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population.
Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.
Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response.
Timing of Myelosuppression During Thiopurine Therapy for Inflammatory Bowel Disease: Implications for Monitoring Recommendations.
Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases.
Whole-Blood Thiopurine S-Methyltransferase Genotype and Phenotype Concordance in Iranian Kurdish Ulcerative Colitis (UC) Patients.
[Erythrocyte activity of thiopurine methyltransferase and treatment with thiopurines in inflammatory bowel disease]
[Frequency of serious adverse events of thiopurine treatment in normal thiopurine S-methyltransferase genotype children with inflammatory bowel disease].
[Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease]
[Not Available].
[Pharmacogenomics in gastroenterologic diseases].
[Significance of thiopurine s-methyltransferase gene test in a clinical case].
[Therapeutic drug monitoring of 6-thioguanine nucleotides in inflammatory bowel disease: interest and limits].
[Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine]
[Thiopurine methyltransferase activity in inflammatory bowel disease. A study on 7046 Spanish patients]
Leukemia
A case of recurrent pancytopenia in a patient with acute promyelocytic leukemia on maintenance chemotherapy and concomitant methyltetrahydrofolate reductase and thiopurine S-methyltransferase mutation?-?review of literature.
A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs.
Comparison of three methods for measuring thiopurine methyltransferase activity in red blood cells and human leukemia cells.
Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells.
Four human thiopurine s-methyltransferase alleles severely affect protein structure and dynamics.
Frequency of thiopurine S-methyltransferase gene variations in Turkish children with acute leukemia.
Frequency of thiopurine S-methyltransferase genetic variation in Thai children with acute leukemia.
Genotyping of thiopurine methyltransferase in patients with acute leukemia using LightCycler PCR.
Genotyping of thiopurine methyltransferase using pyrosequencing.
High-resolution melting analysis of the TPMT gene: a study in the Polish population.
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies.
The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia.
Thiopurine methyltransferase activity in children with acute myeloid leukemia.
Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.
Thiopurine S-Methyltransferase and Methylenetetrahydrofolate Reductase Polymorphisms in Leukemia.
Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.
Thiopurine S-methytransferase Gene Polymorphism in Rheumatoid Arthritis.
[Relationship between single nucleotide polymorphisms in thiopurine methyltransferase gene and tolerance to thiopurines in acute leukemia]
[Studies on the mutation and polymorphism of the TPMT gene in Chinese children with acute leukemia]
Leukemia, Myeloid, Acute
Acute lymphoblastic leukemia.
Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia.
Thiopurine methyltransferase activity in children with acute myeloid leukemia.
Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity.
Leukemia, Promyelocytic, Acute
A case of recurrent pancytopenia in a patient with acute promyelocytic leukemia on maintenance chemotherapy and concomitant methyltetrahydrofolate reductase and thiopurine S-methyltransferase mutation?-?review of literature.
Leukopenia
An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients.
Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase.
Clinical pharmacology of inflammatory bowel disease therapies.
Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: A Multicenter Analysis.
Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice.
Complete remission of refractory pemphigus vulgaris in a Chinese patient with mutated NUDT15 by combination of minimal doses of azathioprine and prednisone.
Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease.
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Influences of Thiopurine Methyltransferase Genotype and Activity on Thiopurine-induced Leukopenia in Korean Patients With Inflammatory Bowel Disease: A Retrospective Cohort Study.
Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
Initiating Azathioprine for Crohn's Disease.
Leukopenia due to Parvovirus B19 in a Crohn's Disease Patient Using Azathioprine.
NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease.
NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis.
NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn's disease.
NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients.
State-of-the-art: immunosuppression and biologic therapy.
The Pharmacogenetics of Immune-Modulating Therapy.
The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease.
Thiopurine S-methyltranferase testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.
TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India.
Update on thiopurine pharmacogenetics in inflammatory bowel disease.
Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID).
[Homozygote deficiency of thiopurine methyltransferase. A contraindication to the use of azathioprine in kidney transplantation]
Liver Diseases
Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.
Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases.
Lupus Erythematosus, Systemic
Aplastic anemia secondary to azathioprine in systemic lupus erythematosus: report of a case with normal thiopurine S-methyltransferase enzyme activity and review of the literature.
Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus.
High frequency of mutant thiopurine S-methyltransferase genotypes in Mexican patients with systemic lupus erythematosus and rheumatoid arthritis.
Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine.
Plasma thiopurine S-methyltransferase levels and azathioprine-related adverse events in patients with Behçet's disease.
Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus.
Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine.
Lymphoma, Non-Hodgkin
DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Multiple Sclerosis
Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms.
Thiopurine methyltransferase activity in a Spanish population sample: decrease of enzymatic activity in multiple sclerosis patients.
Myasthenia Gravis
A New Thiopurine S-Methyltransferase Haplotype Associated With Intolerance to Azathioprine.
A new thiopurine s-methyltransferase haplotype associated with intolerance to azathioprine.
Myelodysplastic Syndromes
Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity.
Neoplasm, Residual
Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003.
Neoplasms
A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.
Genetic polymorphisms influencing therapy and susceptibility to rejection in organ allograft recipients.
Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned.
In Vitro Protein Stability of Two Naturally Occurring Thiopurine S-Methyltransferase Variants: Biophysical Characterization of TPMT*6 and TPMT*8.
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes.
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: Influence on cure rates and risk of second cancer.
Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents.
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.
Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
[Cancer chemotherapy and drug metabolism enzyme]
Neoplasms, Second Primary
Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers.
Neuromyelitis Optica
Association between TPMT*3C and decreased thiopurine S-methyltransferase activity in patients with neuromyelitis optica spectrum disorders in China.
WITHDRAWN: Association between TPMT*3C and decreased thiopurine S-methyltransferase activity in patients with neuromyelitis optica spectrum disorders in China.
Neutropenia
Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.
Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine.
[Homozygote deficiency of thiopurine methyltransferase. A contraindication to the use of azathioprine in kidney transplantation]
Osteoporosis
Treatment of autoimmune blistering diseases.
Ototoxicity
Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
Pancreatitis
TPMT and HLA-DQA1-HLA-DRB genetic profiling to guide the use of azathioprine in the treatment of interstitial lung disease: First experience.
Pancytopenia
A case of recurrent pancytopenia in a patient with acute promyelocytic leukemia on maintenance chemotherapy and concomitant methyltetrahydrofolate reductase and thiopurine S-methyltransferase mutation?-?review of literature.
Autoimmune hepatitis with sclerosing cholangitis in a patient with thiopurine methyltransferase deficiency: case presentation.
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.
Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase.
Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis.
Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age.
Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency.
Severe pancytopenia and aspergillosis caused by thioguanine in a thiopurine S-methyltransferase deficient patient: a case report.
Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease.
Pemphigus
Complete remission of refractory pemphigus vulgaris in a Chinese patient with mutated NUDT15 by combination of minimal doses of azathioprine and prednisone.
Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris.
Thiopurine S-methyltransferase and Pemphigus Vulgaris: A Phenotype-Genotype Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.
A personalized approach to cancer treatment: how biomarkers can help.
Allelic variants of the thiopurine methyltransferase (TPMT) gene in the Colombian population.
Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
Analysis of Thiopurine S-Methyltransferase Deficient Alleles in Acute Lymphoblastic Leukemia Patients in Mexican Patients.
Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
Assessment of Thiopurine-based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia.
Clinical implication of thiopurine methyltransferase polymorphism in children with acute lymphoblastic leukemia: A preliminary Egyptian study.
Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?
Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography.
Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.
Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia.
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.
Genetic Polymorphism of Thiopurine S-methyltransferase in Children with Acute Lymphoblastic Leukemia in Jordan
Genetic Polymorphisms of Drug-Metabolizing Enzymes Involved in 6-Mercaptopurine-Induced Myelosuppression in Thai Pediatric Acute Lymphoblastic Leukemia Patients.
Impact of age, gender and haplotypes of thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) genes on 6-mercaptopurine toxicity in children with acute lymphoblastic leukemia.
Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.
Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6- mercaptopurine toxicity in children with acute lymphoblastic leukemia.
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina.
Pharmacogenomics and ALL treatment: How to optimize therapy.
Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia.
Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.
Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004.
Role of TPMT and ITPA variants in mercaptopurine disposition.
Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency.
Star Allele-Based Haplotyping versus Gene-Wise Variant Burden Scoring for Predicting 6-Mercaptopurine Intolerance in Pediatric Acute Lymphoblastic Leukemia Patients.
Structural Characteristics Determine the Cause of the Low Enzyme Activity of Two Thiopurine S-Methyltransferase Allelic Variants: A Biophysical Characterization of TPMT*2 and TPMT*5.
The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia.
The Relationship of Genetics, Nursing Practice, and Informatics Tools in 6-Mercaptopurine Dosing in Pediatric Oncology [Formula: see text].
The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
Thiopurine methyl transferase: activity and genotyping in patients with acute lymphoblastic leukemia.
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
Thiopurine methyltransferase activity in children with acute myeloid leukemia.
Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
Thiopurine methyltransferase genotype and childhood acute lymphoblastic leukemia.
Thiopurine methyltransferase genotyping in Palestinian childhood acute lymphoblastic leukemia patients.
Thiopurine methyltransferase in acute lymphoblastic leukemia.
Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia.
Thiopurine methyltransferase polymorphisms in a multiracial asian population and children with acute lymphoblastic leukemia.
Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia.
Thiopurine methyltransferase: a review and a clinical pilot study.
Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data.
Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: The Polish multicenter analysis.
Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia.
Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.
Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia.
Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response.
Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Utilization of Thiopurine Metabolites and Allopurinol in Pediatric Acute Lymphoblastic Leukemia: Consideration for an Algorithmic Approach.
[Correlations between 6-mercaptopurine treatment-related adverse reactions in children with acute lymphoblastic leukemia and polymorphisms of thiopurine methyltransferase gene].
[Significance of thiopurine s-methyltransferase gene test in a clinical case].
[The effect of the adverse events with thiopurine S-methyltransferase gene mutation on outcome of childhood acute lymphoblastic leukemia].
[Thiopurine S-Methyltransferase Gene Sequence Analysis of ALL Children Severely Intolerant to 6-Mercaptopurine].
Protein Deficiency
Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C.
Rheumatic Diseases
Characterisation of novel defective thiopurine S-methyltransferase allelic variants.
The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.
[Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases]
Scleroderma, Systemic
Thiopurine methyltransferase activity in the erythrocytes of adults and children: and HPLC-linked assay.
Spondylarthritis
Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis.
Systemic Vasculitis
Plasma thiopurine S-methyltransferase levels and azathioprine-related adverse events in patients with Behçet's disease.
thiopurine s-methyltransferase deficiency
Acute lymphoblastic leukemia.
Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls.
Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
Arrayed primer extension: a robust and reliable genotyping platform for the diagnosis of single gene disorders: beta-thalassemia and thiopurine methyltransferase deficiency.
Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study.
Autoimmune hepatitis with sclerosing cholangitis in a patient with thiopurine methyltransferase deficiency: case presentation.
Autoimmune liver disease.
Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase.
Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms.
Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation.
Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.
Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.
Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
Increasing relevance of pharmacogenetics of drug metabolism in clinical practice.
Molecular diagnosis of thiopurine S-methyltransferase deficiency.
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.
Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency.
Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease.
Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis.
Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
Thiopurine S-methyltransferase activity in a Chinese population.
Thiopurine S-methyltransferase deficiency associated with a novel mutation.
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity.
Update on thiopurine pharmacogenetics in inflammatory bowel disease.
[Homozygote deficiency of thiopurine methyltransferase. A contraindication to the use of azathioprine in kidney transplantation]
Thrombocytopenia
Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
Uremia
Human thiopurine S-methyltransferase activity in uremia and after renal transplantation.
Vasculitis
Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: A retrospective cohort study.
Whooping Cough
A tellurite-resistance genetic determinant from phytopathogenic pseudomonads encodes a thiopurine methyltransferase: evidence of a widely-conserved family of methyltransferases.
xanthine oxidase deficiency
[Hematotoxicity caused by azathioprine genetically determined and aggravated by xanthine oxidase deficiency in a patient following renal transplantation]